Top Markets
Coin of the day
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

4581
주식 순위 #3839
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
주가
$55.98
마지막 동기화: 2024-04-08
시가총액
$4.59B
변동 (1일)
-1.20%
변동 (1년)
0.00%
국가
JP
거래 Taisho Pharmaceutical Holdings Co., Ltd. (4581)

카테고리

B의 시가 총액을 가진 4581의 가격
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
4581
$55.98
의 시가총액 Taisho Pharmaceutical Holdings Co., Ltd.(4581)
시가총액: $4.59B
August 2026 기준으로 Taisho Pharmaceutical Holdings Co., Ltd.의 시가총액은 $4.59B입니다. 이는 당사 데이터에 따르면 Taisho Pharmaceutical Holdings Co., Ltd.이 세계에서 3839th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2011부터 2026까지 Taisho Pharmaceutical Holdings Co., Ltd.의 시가총액 기록
4581 가장 인기있는 상위 5 가지 stocks과 비교하여
4581의 가격 자산 b b의 시장 결과
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$62,860.00 $4.59B
$5.152T +112,191.92%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$55,351.35 $4.59B
$4.537T +98,778.61%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$50,856.25 $4.59B
$4.169T +90,748.65%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$44,436.43 $4.59B
$3.642T +79,280.41%
Taisho Pharmaceutical Holdings Co., Ltd. Taisho Pharmaceutical Holdings Co., Ltd.
$34,217.20 $4.59B
$2.805T +61,024.96%